vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Inspirato Inc (ISPO). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $55.5M, roughly 1.6× Inspirato Inc). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -19.6%). Inspirato Inc produced more free cash flow last quarter ($-3.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -11.4%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Inspirato Inc is a luxury travel and hospitality subscription service provider catering primarily to high-net-worth consumers across North America. It offers curated premium villa rentals, exclusive resort access, customized trip planning, and corporate travel incentive solutions for enterprise clients.
IOVA vs ISPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $55.5M |
| Net Profit | — | $-4.5M |
| Gross Margin | 67.4% | 31.4% |
| Operating Margin | -84.7% | -8.0% |
| Net Margin | — | -8.1% |
| Revenue YoY | 17.7% | -19.6% |
| Net Profit YoY | — | -204.4% |
| EPS (diluted) | — | $-0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | — | ||
| Q3 25 | $67.5M | $55.5M | ||
| Q2 25 | $60.0M | $63.1M | ||
| Q1 25 | $49.3M | $65.9M | ||
| Q4 24 | $73.7M | $63.1M | ||
| Q3 24 | $58.6M | $69.1M | ||
| Q2 24 | $31.1M | $67.4M | ||
| Q1 24 | $715.0K | $80.2M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $-4.5M | ||
| Q2 25 | $-111.7M | $-5.3M | ||
| Q1 25 | $-116.2M | $1.6M | ||
| Q4 24 | — | $-2.3M | ||
| Q3 24 | $-83.5M | $4.3M | ||
| Q2 24 | $-97.1M | $-8.7M | ||
| Q1 24 | $-113.0M | $1.3M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | 31.4% | ||
| Q2 25 | 5.5% | 27.5% | ||
| Q1 25 | -0.8% | 38.8% | ||
| Q4 24 | 68.7% | 34.7% | ||
| Q3 24 | 46.2% | 71.5% | ||
| Q2 24 | -0.8% | 24.0% | ||
| Q1 24 | — | 39.5% |
| Q4 25 | -84.7% | — | ||
| Q3 25 | -140.7% | -8.0% | ||
| Q2 25 | -189.8% | -8.3% | ||
| Q1 25 | -245.8% | 2.5% | ||
| Q4 24 | -117.5% | -3.2% | ||
| Q3 24 | -152.1% | 9.8% | ||
| Q2 24 | -327.6% | -22.8% | ||
| Q1 24 | -16464.6% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | -8.1% | ||
| Q2 25 | -186.2% | -8.4% | ||
| Q1 25 | -235.5% | 2.5% | ||
| Q4 24 | — | -3.6% | ||
| Q3 24 | -142.7% | 6.3% | ||
| Q2 24 | -312.2% | -12.9% | ||
| Q1 24 | -15800.8% | 1.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | $-0.33 | $-0.42 | ||
| Q1 25 | $-0.36 | $0.12 | ||
| Q4 24 | $-0.24 | $0.98 | ||
| Q3 24 | $-0.28 | $0.62 | ||
| Q2 24 | $-0.34 | $-2.33 | ||
| Q1 24 | $-0.42 | $-0.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $13.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $-134.0M |
| Total Assets | $913.2M | $228.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | — | ||
| Q3 25 | $300.8M | $13.7M | ||
| Q2 25 | $301.2M | $16.7M | ||
| Q1 25 | $359.7M | $16.4M | ||
| Q4 24 | $323.8M | $21.8M | ||
| Q3 24 | $397.5M | $13.5M | ||
| Q2 24 | $412.5M | $18.8M | ||
| Q1 24 | $356.2M | $22.6M |
| Q4 25 | $698.6M | — | ||
| Q3 25 | $702.3M | $-134.0M | ||
| Q2 25 | $698.5M | $-129.7M | ||
| Q1 25 | $767.9M | $-125.2M | ||
| Q4 24 | $710.4M | $-129.9M | ||
| Q3 24 | $773.5M | $-134.6M | ||
| Q2 24 | $768.5M | $-35.2M | ||
| Q1 24 | $680.0M | $-27.5M |
| Q4 25 | $913.2M | — | ||
| Q3 25 | $904.9M | $228.3M | ||
| Q2 25 | $907.4M | $252.6M | ||
| Q1 25 | $966.7M | $270.1M | ||
| Q4 24 | $910.4M | $273.9M | ||
| Q3 24 | $991.1M | $273.3M | ||
| Q2 24 | $964.3M | $301.7M | ||
| Q1 24 | $869.8M | $313.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-2.2M |
| Free Cash FlowOCF − Capex | $-61.9M | $-3.0M |
| FCF MarginFCF / Revenue | -71.3% | -5.4% |
| Capex IntensityCapex / Revenue | 10.7% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $-31.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | — | ||
| Q3 25 | $-78.7M | $-2.2M | ||
| Q2 25 | $-67.4M | $1.1M | ||
| Q1 25 | $-103.7M | $-6.6M | ||
| Q4 24 | $-73.3M | $-15.8M | ||
| Q3 24 | $-59.0M | $-13.7M | ||
| Q2 24 | $-98.4M | $-1.8M | ||
| Q1 24 | $-122.3M | $-7.2M |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | $-3.0M | ||
| Q2 25 | $-74.9M | $468.0K | ||
| Q1 25 | $-109.9M | $-7.5M | ||
| Q4 24 | $-77.5M | $-21.2M | ||
| Q3 24 | $-61.3M | $-14.8M | ||
| Q2 24 | $-98.9M | $-3.7M | ||
| Q1 24 | $-126.5M | $-8.5M |
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | -5.4% | ||
| Q2 25 | -124.9% | 0.7% | ||
| Q1 25 | -222.8% | -11.4% | ||
| Q4 24 | -105.1% | -33.7% | ||
| Q3 24 | -104.6% | -21.5% | ||
| Q2 24 | -317.9% | -5.5% | ||
| Q1 24 | -17685.3% | -10.6% |
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | 1.4% | ||
| Q2 25 | 12.4% | 1.0% | ||
| Q1 25 | 12.6% | 1.3% | ||
| Q4 24 | 5.7% | 8.7% | ||
| Q3 24 | 3.9% | 1.6% | ||
| Q2 24 | 1.4% | 2.8% | ||
| Q1 24 | 583.4% | 1.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4.09× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -3.16× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -5.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
ISPO
| Residence And Hotel Travel | $25.9M | 47% |
| Subscription | $19.4M | 35% |
| Experiences And Bespoke Travel | $8.0M | 14% |
| Rewards And Other Revenue | $2.3M | 4% |
